We randomized 47 insulin-treated non-proteinuric patients with satisfactory controlled T2DM and estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m2either to continue insulin therapy (control) or to receive combined insulin-vildagliptin treatment (VIG group). This evidence concerns the gene INS and type 2 diabetes mellitus.